US to pay Sanofi, GlaxoSmithKline up to $2.1B for development, 100M doses of coronavirus vaccine

Sanofi, which received about $30 million from HHS in February for the vaccines development, prepares to begin scientific trials in September and get in late-stage screening by the end of 2020. It wants to seek regulative approval during the very first half of 2021.

More short articles on drug store: Michigan, Pennsylvania may ban drugmakers from giving presents to physiciansUS sending Texas medical facilities 500 cases of remdesivir as COVID-19 cases surgeOperation Warp Speed: a timeline up until now.

Majority of the funding is assigned for the vaccines advancement, and the rest will go to manufacturing costs and an initial supply of 100 million doses. The U.S. has the option to obtain an extra 500 million dosages later on.

The U.S. government signed an agreement July 31 with Sanofi and GlaxoSmithKline to pay up to $2.1 billion for the development and supply of a COVID-19 vaccine.

The majority of the financing will go to Sanofi, which is establishing the vaccine prospect based on recombinant protein-centric innovation used in its influenza vaccine. Sanofi is partnering with GlaxoSmithKline to integrate its adjuvant technology into the vaccine for enhanced efficacy.

Michigan, Pennsylvania may ban drugmakers from giving gifts to doctors.

Katie Adams –
Friday, July 31st, 2020
Print|Email.

© Copyright ASC COMMUNICATIONS 2020. Intrigued in LINKING to or REPRINTING this content? View our policies by click on this link.

© Copyright ASC COMMUNICATIONS 2020. Intrigued in LINKING to or REPRINTING this content? View our policies by clicking here.